zanidatamab for her2-amplified, unresectable, locally advanced or metastatic biliary tract cancer
Published 1 year ago • 853 plays • Length 7:37Download video MP4
Download video MP3
Similar videos
-
2:12
dr pant on the utility of zanidatamab in previously treated her2 biliary tract cancer
-
2:24
asco 2024 top 5 zanidatamab phase 2 her2 questions on biliary tract cancer
-
1:37
molecular testing in unresectable biliary tract cancer | daniel catenacci, md | asco22 gi updates
-
1:01:07
protocols for her2-expressing gi cancers: refining btc and gea care with targeted agents
-
2:13
zanidatamab chemo as 1l therapy in her2-expressing gea
-
6:49
treating her2-mutant advanced biliary tract cancer with neratinib
-
2:21
sgntuc-019: tucatinib trastuzumab for previously treated her2 metastatic biliary tract cancer
-
5:00
patient case: how do her2-directed therapies fit into the biliary tract cancer treatment landscape?
-
1:01:35
her2 treatment
-
0:52
the significance of tucatinib trastuzumab as a chemotherapy-free option for her2 metastatic btc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
0:36
advances in treatment for pancreatic cancer
-
0:58
exploring biosimilars in the field of breast cancer
-
6:01
ado-trastuzumab emansine in patients with her2 amplified salivary gland cancers: results from a ...
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
1:46
new promise in treating mbc: combining anti-ar therapy with chemotherapy
-
1:20
final results from the phase 2 summit basket trial: targeting her2 advanced btcs with neratinib
-
2:47
her2 inflammatory breast cancer: neoadjuvant approaches